Josh Ludwig Joins Industry Experts in Roundtable Discussion: Redefining Manufacturing
In today’s modern world, the manufacturing of cell and gene therapies demands streamlined and proficient processes to align with the constant and rapid progress and breakthroughs in the industry. The advancements in the cell and gene therapies sector extend beyond its products alone. Upgrading technologies and adapting supply chains play an equally pivotal role. Hence, it begs the question: What is the current state of this environment, and what does the future hold?
To gain insights into manufacturing in the age of advanced therapies, The Medicine Maker consulted four experts in the field:
- Dalip Sethi, scientific lead, Terumo Blood and Cell Technologies
- Vered Caplan, CEO, Orgenesis
- Josh Ludwig, Global Commercial Director, ScaleReady
- Becky Butler CapSVP, Business Development, Advanced Therapies for BioBridge Global
Josh Ludwig discusses the need to redefine manufacturing to better treat more patients with various modalities around the world and meet the growing demand of the treatments. The continued thought process around the evolution of manufacturing is, “What can we do to engineer the most simple process and tools that are also flexible?” The answer is not just-in-time manufacturing solutions. Instead, it’s tools that are ready and available today to scale up and out to serve the growing patient population.
Josh Ludwig is the Global Commercial Director for ScaleReady and has more than a decade of experience working with Wilson Wolf G-Rex bioreactors within cell and gene-modified therapy manufacturing.
Related Insights
Multiply Labs and Wilson Wolf Join Forces to Automate Cell Therapy Manufacturing with G-Rex® Bioreactors
Multiply Labs and Wilson Wolf are partnering to automate G-Rex® bioreactors for cheaper, more accessible cell therapy manufacturing. This partnership focuses on automating Wilson Wolf's innovative G-Rex® bioreactors, aiming to revolutionize CGT manufacturing.
Unlocking the Potential of Stem Cells: A New Frontier in Cancer Immunotherapy
Cancer immunotherapy has revolutionized treatment, but existing strategies have limitations. Natural Killer (NK) cells, part of our immune system, show amazing potential to destroy both blood and solid tumor cancers. However, getting enough consistently potent NK cells for therapy is tricky.
Innovating Cell Therapy Manufacturing: The Path to Decentralization and GMP Success
Cell therapies are exploding with potential, offering groundbreaking new treatments for a wide range of diseases. Yet, a central challenge lies in bringing these complex therapies out of the lab and into the real world. In a recent panel discussion, Josh Ludwig (Global Commercial Director, ScaleReady) and Stuart Curbishley (Chief Manufacturing & Development Officer, Adthera Bio) shed light on this complex transition.
Advancing Immune Cell Therapies Through Efficient Cell Culture Techniques
In an expert roundtable discussion by Cell and Gene Therapy Insights, the potential of cell culture in immune cell therapies takes center stage, offering promising possibilities for the future of regenerative medicine.
Josh Ludwig Discusses Innovative Approaches to Cell & Gene Therapy Manufacturing in Medical Alley Podcast
In an enlightening episode of the Medical Alley Podcast, Josh Ludwig, the Global Director of Commercial Operations at ScaleReady, shares invaluable insights into the world of cell and gene therapy manufacturing.
Josh Ludwig Shares Vision for Streamlined Cell and Gene Therapy with Medical Alley
In an interview published by Medical Alley, Josh Ludwig, the Global Director of Commercial Operations at ScaleReady, discussed ScaleReady's innovative approach to revolutionizing the cell and gene therapy industry.
Josh Ludwig Shares Insights on Achieving Scalable and Cost-Effective Cell and Gene Therapy Manufacturing
This interview provides valuable insights into Ludwig's vision for the future of CGT manufacturing, focusing on creating a robust and accessible platform that empowers the industry to deliver life-changing therapies to patients worldwide.
Early Adoption and Partnerships — The Secret to Commercialization Success in Regenerative Medicine
The power of collaborative partnerships is highlighted as a game-changer in driving commercialization efforts. By leveraging the expertise of multiple stakeholders, including researchers, clinicians and industry players, cell and gene therapy manufacturers can navigate complex challenges and accelerate the delivery of groundbreaking therapies to patients.
Simplifying Processes and Prioritizing Standardization: A Better Approach to Scaling Cell and Gene Therapies
The road to scaling cell and gene therapies successfully lies in prioritizing simplicity and standardization. By addressing complexity first and then implementing automation strategically, the industry can bring life-changing treatments to more patients worldwide.
Josh Ludwig Discusses Key Themes at ISCT 2023 Paris Meeting
The future of cell and gene therapy manufacturing is poised for transformative advancements, driven by key themes that aim to enhance scalability, efficiency, and safety. One crucial theme is automation and process standardization.
Shaping the Future of Cell and Gene Therapy Manufacturing: Key Trends and Innovations
Understand insights into the key trends that are redefining manufacturing processes in the rapidly evolving sector of CGT as discussed at the recent ISCT 2023 Annual Meeting.
Are you ready to scale?
Let’s talk more about how ScaleReady can advance your cell and gene therapy research and manufacturing with ingenious efficiency.